The quick read
Harrow’s filed numbers show revenue growing at a pace most pharmaceutical companies never see, more than fivefold in five years. The 10-Q filed for the quarter ended June 30, 2026 shows total equity of $14.8 million sitting beneath $402 million in total liabilities, meaning the company is funded almost entirely by debt. The stock, meanwhile, has fallen nearly half from its 52-week high. Fast growth and near-insolvent leverage are not supposed to coexist, and that contradiction is the story.
What the filing actually shows
Harrow started this decade as a compounding pharmacy, mixing custom ophthalmic drugs for eye surgeons who could not get what they needed off the shelf. That business was real but small. Then management made a bet: stop being a compounder and become a branded pharmaceutical company, acquiring FDA-approved eye-care drugs and building a sales force to push them. By the fiscal year ended December 31, 2025, revenue had reached $272 million. That is the kind of growth that makes investors lean forward.
The most recent complete filing, the 10-Q for the quarter ended June 30, 2026, is where the lean turns into a squint. Revenue for the quarter was $70.7 million, up modestly from the same quarter a year earlier. That sounds fine. But the net loss for just those three months was substantial, and the six-month loss through June reached $44.9 million. A company earning more each year and losing more each year at the same time is carrying a cost structure that revenue has not yet caught up to.
The branded pivot, in plain numbers
The Q2 2026 revenue breakdown tells the strategic story clearly. Of the $70.7 million in total revenue, $56.1 million came from branded products and the remainder from compounding, the old core business. Two drugs carry most of the branded weight: VEVYE, a dry-eye treatment, more than doubled year-over-year in the quarter. IHEEZO, an anesthetic used in eye procedures, contributed a meaningful share as well. The original compounding revenue, meanwhile, is shrinking as a share of the whole, which is exactly what management intended.
The risk hiding inside that success is concentration. Two products account for roughly two-thirds of total revenue. Harrow’s own disclosures, relayed by Investing.com’s transcript of the Q2 2026 earnings call, flag that IHEEZO’s pass-through reimbursement status in ambulatory surgery centers ended April 1, 2026. Pass-through status is a Medicare designation that lets hospitals bill separately for a new drug, making it easier to adopt. When it expires, the drug competes on its own merits inside tighter budgets. Management responded by raising IHEEZO’s net price roughly 25% effective July 1, 2026, a move that could offset volume pressure or accelerate it, depending on how payers respond. The data to judge that is in the Q3 2026 results, which Harrow announced are scheduled for release on November 9, 2026.
The leverage problem, stated plainly
Here is the number that changes the character of everything else. As of June 30, 2026, Harrow’s notes payable stood at $292.4 million. Total stockholders’ equity, the cushion that absorbs losses before creditors feel pain, was $14.8 million. Think of it this way: a household with debts many times its net worth is not in a stable position, even if its income is rising. One bad quarter does not wipe out a well-capitalized company. It could meaningfully alter the options available to a company in Harrow’s position.
Cash used in operations during the first half of 2026 exceeded eighteen million dollars, meaning the business consumed cash rather than generating it. Cash on hand at June 30 provides a runway, but not an unlimited one. Management’s full-year 2026 guidance, reiterated at the August 11 earnings call, calls for revenue between $350 million and $365 million and adjusted EBITDA between $80 million and $100 million. Adjusted EBITDA is a measure of operating cash generation before interest, taxes, and non-cash charges. Reaching it would matter enormously here, because interest on nearly three hundred million dollars in debt is a real and recurring cash cost that adjusted figures set aside.
Seeking Alpha, as noted by Kalkine, calculated that hitting the full-year guidance requires Harrow to generate more than twice the first half’s revenue in the second half alone. That is the math the mood is betting on.
What changed in 2026 and what is still open
Three things shifted materially since the year began. Harrow acquired TYRVAYA, a nasal-spray dry-eye treatment, closing the deal October 5, 2026, adding another product to the portfolio and another obligation to the balance sheet. On November 2, 2026, the company launched HarrowRx, a platform built inside electronic medical record systems to make it easier for eye doctors to prescribe Harrow’s drugs without leaving their workflow. CEO Mark L. Baum described it as reducing complexity for prescribers. Whether it moves the revenue needle is unknown. And the Q3 2026 results, due November 9, 2026, will be the first filed evidence of whether the IHEEZO price increase held, whether VEVYE’s expanded formulary coverage from August 1 translated into volume, and whether the second-half acceleration management promised is actually arriving.
Based on trailing twelve-month revenue per the filed 10-Q and 10-K, the current price-to-sales ratio sits below the company’s own five-year median, a gap that could reflect either a discount or a structural re-rating, depending on whether the second-half revenue acceleration materializes. The math, meaning what the filed fundamentals show, is a company growing fast and burning cash against a leveraged balance sheet with thin equity. The mood, meaning what the market is currently paying, prices in either doubt about the growth story or fear about the debt, or both. Which reading is correct depends heavily on a filing that does not exist yet. The Q3 2026 filing is not a routine data point in this case; it is the first evidence that will confirm or challenge the second-half acceleration thesis on which the current capital structure depends.
Reading the numbers
- $70.7 million, Q2 2026 revenue. What it is: total sales for the three months ended June 30, 2026, per the 10-Q filed August 10, 2026. What it means here: revenue is growing, but the rate of growth (11% year-over-year) is slower than the double-digit annual rates Harrow posted in prior years. Everyday terms: a shop that grew sales 50% a year for four years and is now growing 11% is not failing, but it is changing character.
- $14.8 million, total stockholders’ equity. What it is: the difference between everything the company owns ($416.8 million in assets) and everything it owes ($402.0 million in liabilities), per the same 10-Q. What it means here: this is the financial cushion. It is thin. Everyday terms: a business worth $416,800 with $402,000 in debts has $14,800 left for its owners. A single bad quarter of losses could push that to zero.
- $292.4 million, notes payable. What it is: the company’s outstanding debt obligations as of June 30, 2026. What it means here: debt at this level relative to equity means interest payments are a fixed, unavoidable cost that must be covered before the company retains anything. Everyday terms: if a household earns $70,000 a year and carries $292,000 in loans, every dollar of income is spoken for before any savings begin.
- $272 million, FY2025 revenue vs. $49 million in FY2020. What it is: five years of annual revenue from the 2025 10-K and the 2023 10-K. What it means here: the business is genuinely larger. Revenue grew more than fivefold in five years. Everyday terms: a shop that took in $49 a day in 2020 and now takes in $272 a day has built something real, even if it has not yet turned profitable.
For the standing yardsticks on Dow: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Dow.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- Harrow Q2 2026 earnings press release
- Q2 2026 earnings call transcript (Investing.com)
- Harrow investor news releases
- Kalkine on HarrowRx platform
